Dr.Reddy’s Laboratories launched FDA approved lansoprozole-OTC capsule in US market.

| |

Dr.Reddys LabMay 22 Mumbai: Dr.Reddy’s Laboratories launched its over-the-counter lansoprazole delayed-release capsules in the US market following ANDA approval by the USFDA.

The Hyderabad-based company will market the product under store brand labels in the US market.

The tablets are generally indicated for treating rheumatoid arthritis and osteoarthritis.

The product is the bioequivalent version of Novartis Consumer Health’s Prevacid 24 HR capsule.it received Rx-to OTC switch approval from the FDA on March 18, 2009.

The Prevacid 24 HR capsule market had brand sales of approximately $115 million for the twelve months ending March 2012 according to SymphonyIRI InfoScan Reviews™.

Rx-to-OTC is the process of transferring FDA approval for prescription medications to non-prescription or over-the-couonter (OTC) status is called as Rx-to-OTC switch.

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.

Last week, the company also launched Clopidogrel tablets, USP, a bioequivalent generic version of Plavix in the US market.

News Gathered by India News

Posted by on Tuesday, May 22nd, 2012. Filed under Bangalore, Business, Health, India News, Life Style, World. You can follow any responses to this entry through the RSS 2.0. You can leave a response or trackback to this entry

Leave a Reply